Skip to main content

Carl R. Woese Institute for Genomic Biology

Where Science Meets Society

Scientists test nanoparticle drug delivery in dogs with osteosarcoma

At the University of Illinois, an engineer teamed up with a veterinarian to test a bone cancer drug delivery system in animals bigger than the standard animal model, the mouse. They chose dogs – mammals closer in size and biology to humans – with naturally occurring bone cancers, which also are a lot like human bone tumors.

Cancer drug first tested in pet dogs begins human trials

Cancer drug first tested in pet dogs begins human trials

A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously occurring cancers, and is still in clinical trials in dogs with osteosarcoma.

Cancer Drug Tested in Pet Dogs is Now Bound for Human Trials

Cancer Drug Tested in Pet Dogs is Now Bound for Human Trials

Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.

Subscribe to Dogs